🏛️ Verified NIH Record • Updated 2026-07-20
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes (NCT07284875)
🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Kailera
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (11 items).
Location: Kailera Clinical Site — Anniston, Alabama
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Current diagnosis or history of diabetes mellitus.
- Started medications within 3 months prior to Screening that may cause significant weight change, including, but not limited to: tricyclic antidepressants, atypical antipsychotics, mood stabilizers, or phentermine.
- Unstable weight defined as self-reported change in body weight exceeding 5% within 3 months prior to Screening.
- Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.
- Uncontrolled hypertension or unstable cardiovascular disease.
- History of chronic or acute pancreatitis.
- Known clinically significant gastric-emptying abnormality or chronic treatment with medications that directly affect gastrointestinal motility.
- History of suicide attempt.
- History of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder.
- Received treatment with semaglutide, tirzepatide, GLP-1 receptor agonist, GLP-1/glucose-dependent insulinotropic polypeptide (GIP), or glucagon receptor agonist within 3 months prior to Screening. Note: Additional inclusion/exclusion criteria may apply, per protocol.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (88 Sites)
- Kailera Clinical Site — Anniston, Alabama
- Kailera Clinical Site — Birmingham, Alabama
- Kailera Clinical Site — Cullman, Alabama
- Kailera Clinical Site — Sun City, Arizona
- Kailera Clinical Site — Escondido, California
- Kailera Clinical Site — Toluca Lake, California
- Kailera Clinical Site — Aurora, Colorado
- Kailera Clinical Site — Bridgeport, Connecticut
- Kailera Clinical Site — Jupiter, Florida
- Kailera Clinical Site — Lilburn, Georgia
- Kailera Clinical Site — Springfield, Illinois
- Kailera Clinical Site — Columbia, Maryland
- Kailera Clinical Site — Las Vegas, Nevada
- Kailera Clinical Site — Rochester, New York
- Kailera Clinical Site — Morehead City, North Carolina
- Kailera Clinical Site — Chickasha, Oklahoma
- Kailera Clinical Site — Mauldin, South Carolina
- Kailera Clinical Site — Chattanooga, Tennessee
- Kailera Clinical Site — Amarillo, Texas
- Kailera Clinical Site — Bellaire, Texas
- Kailera Clinical Site — DeSoto, Texas
- Kailera Clinical Site — Tomball, Texas
- Kailera Clinical Site — Salt Lake City, Utah
- Kailera Clinical Site — Danville, Virginia
- Kailera Clinical Site — San Nicolás de los Arroyos, Buenos Aires
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.